177 related articles for article (PubMed ID: 36935014)
41. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
McGaugh S; Kallis P; De Benedetto A; Thomas RM
Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
[TBL] [Abstract][Full Text] [Related]
42. Small molecules in the treatment of systemic lupus erythematosus.
Markopoulou A; Kyttaris VC
Clin Immunol; 2013 Sep; 148(3):359-68. PubMed ID: 23158694
[TBL] [Abstract][Full Text] [Related]
43. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Kahn J; Deverapalli SC; Rosmarin D
Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
[TBL] [Abstract][Full Text] [Related]
44. Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus.
Udompanich S; Chanprapaph K; Suchonwanit P
Am J Clin Dermatol; 2018 Oct; 19(5):679-694. PubMed ID: 29948959
[TBL] [Abstract][Full Text] [Related]
45. Treatment of systemic lupus erythematosus - 2013 update.
Belmont HM
Bull Hosp Jt Dis (2013); 2013; 71(3):208-13. PubMed ID: 24151947
[TBL] [Abstract][Full Text] [Related]
46. Plaque-like Cutaneous Lupus Mucinosis as the First Sign of Systemic Lupus Erythematosus.
Gao M; Sheng N; Yang X; Jiang Y
Acta Derm Venereol; 2020 Feb; 100(4):adv00048. PubMed ID: 31774542
[No Abstract] [Full Text] [Related]
47. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case.
Uthman I; Taher A; Abbas O; Menassa J; Ghosn S
Dermatology; 2008; 216(3):257-9. PubMed ID: 18182821
[No Abstract] [Full Text] [Related]
48. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
Niebel D; de Vos L; Fetter T; Brägelmann C; Wenzel J
Am J Clin Dermatol; 2023 Jul; 24(4):521-540. PubMed ID: 37140884
[TBL] [Abstract][Full Text] [Related]
49. A review of the evidence and cost of therapies for cutaneous lupus erythematosus.
Rosen JD; Paul S; Maderal A
Lupus; 2019 Jun; 28(7):799-805. PubMed ID: 31042129
[TBL] [Abstract][Full Text] [Related]
50. What's new in the management of lupus since 2000?
Wallace DJ
J Clin Rheumatol; 2006 Dec; 12(6):307-13. PubMed ID: 17149066
[No Abstract] [Full Text] [Related]
51. Janus kinase inhibitors in dermatology: Part II. A comprehensive review.
Chapman S; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):414-422. PubMed ID: 34228996
[TBL] [Abstract][Full Text] [Related]
52. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
53. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
[TBL] [Abstract][Full Text] [Related]
54. Fumaric acid esters: a new therapeutic option for skin manifestations in lupus erythematosus?
Kuhn A; Landmann A; Bonsmann G
Br J Dermatol; 2017 Feb; 176(2):301-302. PubMed ID: 28244075
[No Abstract] [Full Text] [Related]
55. Current Recommendations for the Systemic Treatment of Cutaneous Lupus Erythematosus During Pregnancy.
Kirchner A; Riegert M; Lake E
Cutis; 2022 Feb; 109(2):90-E1. PubMed ID: 35659805
[TBL] [Abstract][Full Text] [Related]
56. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
57. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
Zhang K; Ye K; Tang H; Qi Z; Wang T; Mao J; Zhang X; Jiang S
J Med Chem; 2023 Apr; 66(7):4378-4416. PubMed ID: 36951608
[TBL] [Abstract][Full Text] [Related]
58. Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Wang X; Li M; Zeng X; Wang Q
Rheumatology (Oxford); 2023 Oct; 62(10):e293-e294. PubMed ID: 36943383
[No Abstract] [Full Text] [Related]
59. Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model.
Chan ES; Herlitz LC; Jabbari A
J Invest Dermatol; 2015 Jul; 135(7):1912-1915. PubMed ID: 25789705
[No Abstract] [Full Text] [Related]
60. [Papular mucinosis. A rare cutaneous manifestation of lupus erythematosus].
Storck R; Schirren CG; Meurer M; Kind P
Hautarzt; 1994 Sep; 45(9):642-6. PubMed ID: 7960774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
